Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single nucleotide polymorphisms affecting galantamine binding to acetylcholinesterase in Alzheimer's disease: a structural bioinformatics study.

Journal of computer-aided molecular design - 9 Apr 2026

Islam Nadia, Akçesme Betül

Abstract excerpt

Galantamine, an acetylcholinesterase (AChE) inhibitor used for symptomatic treatment of Alzheimer's disease (AD), shows substantial inter-individual variability in clinical response. Missense single nucleotide polymorphisms (SNPs) within the AChE active-site gorge may modulate inhibitor recognition. In this computational study, binding residues were defined from human AChE inhibitor co-crystal structures and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylcholinesterase
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catalytic Domain

Share to Cholinesterase Inhibitors

Share to Computational Biology

Share to Ligands

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Source

Open in PubMed Open full text

Identifiers

PMID: 41951832
DOI: 10.1007/s10822-026-00805-6
PMCID: PMC13061798

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single nucleotide polymorphisms affecting galantamine binding to acetylcholinesterase in Alzheimer's disease: a structural bioinformatics study.PMID 41951832Read ↗

A new role for the nonpathogenic nonsynonymous single-nucleotide polymorphisms of acetylcholinesterase in the treatment of Alzheimer's disease: a computational study.Semantic proximity Read ↗

In silico analyses of acetylcholinesterase (AChE) and its genetic variants in interaction with the anti‐Alzheimer drug RivastigmineSemantic proximity Read ↗

Structural and dynamics insights into the GBA variants associated with Parkinson's disease.Semantic proximity Read ↗

Pyrimethamine-based targeting of HEXA gene mutations in Tay-Sachs disease: a computational analysisSemantic proximity Read ↗

Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia.Semantic proximity Read ↗

Ligand-induced conformational changes in residues flanking the active site gorge of acetylcholinesterase.Semantic proximity Read ↗

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.Semantic proximity Read ↗

In silico approaches to identify the potential inhibitors of glutamate carboxypeptidase II (GCPII) for neuroprotection.Semantic proximity Read ↗

Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core.Semantic proximity Read ↗

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.Semantic proximity Read ↗

Probing the peripheral site of human butyrylcholinesterase.Semantic proximity Read ↗

Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.